Pluri Inc. - Asset Resilience Ratio

Latest as of December 2025: 25.47%

Pluri Inc. (PLUR) has an Asset Resilience Ratio of 25.47% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check PLUR strategic asset allocation to assess the company's strategic physical and investment asset allocation.

Liquid Assets

$7.79 Million
Cash + Short-term Investments

Total Assets

$30.60 Million
All company assets

Resilience Assessment

Very High
Financial Resilience Level

Asset Resilience Ratio Trend (2007–2025)

This chart shows how Pluri Inc.'s Asset Resilience Ratio has changed over time. See Pluri Inc. net asset quality index to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down Pluri Inc.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of Pluri Inc..

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents $0.00 0%
Short-term Investments $7.79 Million 25.47%
Total Liquid Assets $7.79 Million 25.47%

Asset Resilience Insights

  • Very High Liquidity: Pluri Inc. maintains exceptional liquid asset reserves at 25.47% of total assets.
  • This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
  • The company has significant short-term investments, indicating active treasury management.

Pluri Inc. Industry Peers by Asset Resilience Ratio

Compare Pluri Inc.'s asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
Biotechnology 0.00%
Cyclacel Pharmaceuticals Inc
NASDAQ:CYCC
Biotechnology -55.36%
Krystal Biotech Inc
NASDAQ:KRYS
Biotechnology 23.06%
Verona Pharma PLC ADR
NASDAQ:VRNA
Biotechnology 0.00%
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
Biotechnology 33.37%
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
Biotechnology 8.08%
Hebei Changshan Biochem Pharma
SHE:300255
Biotechnology -0.03%
BB Biotech AG
SW:BION
Biotechnology 0.05%

Annual Asset Resilience Ratio for Pluri Inc. (2007–2025)

The table below shows the annual Asset Resilience Ratio data for Pluri Inc..

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-06-30 38.05% $14.72 Million $38.68 Million -20.65pp
2024-06-30 58.70% $23.20 Million $39.53 Million -9.83pp
2023-06-30 68.53% $34.81 Million $50.80 Million +2.06pp
2022-06-30 66.47% $45.24 Million $68.06 Million +30.43pp
2021-06-30 36.04% $33.71 Million $93.54 Million -21.21pp
2020-06-30 57.25% $37.51 Million $65.53 Million -5.35pp
2019-06-30 62.60% $19.60 Million $31.31 Million +8.49pp
2018-06-30 54.10% $21.08 Million $38.96 Million -2.91pp
2017-06-30 57.01% $21.40 Million $37.53 Million +0.45pp
2016-06-30 56.56% $25.98 Million $45.94 Million +13.40pp
2015-06-30 43.16% $29.42 Million $68.16 Million -23.59pp
2014-06-30 66.75% $49.41 Million $74.02 Million +1.04pp
2013-06-30 65.71% $44.89 Million $68.32 Million +50.90pp
2012-06-30 14.81% $7.02 Million $47.42 Million -10.13pp
2009-06-30 24.94% $1.11 Million $4.46 Million -8.13pp
2008-06-30 33.06% $1.19 Million $3.58 Million -22.81pp
2007-06-30 55.87% $3.76 Million $6.73 Million --
pp = percentage points

About Pluri Inc.

NASDAQ:PLUR USA Biotechnology
Market Cap
$24.24 Million
Market Cap Rank
#24515 Global
#5187 in USA
Share Price
$2.25
Change (1 day)
+0.00%
52-Week Range
$2.25 - $5.79
All Time High
$160.00
About

Pluri Inc., a biotechnology company, engages in the research, development, and manufacture of cell-based products, cell therapeutics, and related technologies for various industries. It develops placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions; and immunotherapy platform. The company's product candidates include PLX-PAD,… Read more